44 results about "Lipofuscin" patented technology

The application belongs to the field of daily chemicals, and discloses a Bifidobacterium adolescentis, the classification name of the Bifidobacterium adolescentis BF23BA001 is Bifidobacterium adolescentis, the preservation number is CGMCC NO.26999, the preservation date is March 31, 2023, the preservation unit is China General Microbiological Culture Collection Center, and the preservation address is No.3, Xibahe Road, Chaoyang District, Beijing City. Compared with other similar bacteria on the market, the bacteria have unique advantages in the production of small molecule peptides and gamma-aminobutyric acid, according to the functional characteristics of the small molecule peptides and gamma-aminobutyric acid, the bacteria have significant anti-wrinkle advantages, and through subsequent functional verification, the bacteria have very important significance for further improving the whitening, brightening, repair and anti-aging effects of yeast fermentation products. In addition, the application also discloses a composition for inhibiting the generation and accumulation of lipofuscin, application based on the composition and cosmetics.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention relates to a composition with antioxidant and brightening effects and capable of delaying skin saccharification as well as a preparation method and application of the composition, and belongs to the field of cosmetics. The composition comprises an ormosia henryi bark extract, tetrahydrocurcumin, a mirabilis jalapa extracting solution, a surfactant, polyol, phospholipid and a solvent. The composition provided by the invention has good illumination stability and high-temperature stability, and the composition provided by the invention is high in bioavailability, and has good antioxidant and brightening effects and lipofuscin and RAGE level inhibition effects.

The invention relates to the technical field of environmental health risk evaluation, in particular to a method for evaluating the risk of Parkinson's disease induced by environmental pollutants. The method for evaluating the risk of inducing the Parkinson's disease by the environmental pollutants comprises the following steps: carrying out a subacute exposure experiment by taking caenorhabditis elegans as a model organism; observing the transport capacity of the caenorhabditis elegans, observing and counting the abnormal movement ability of the caenorhabditis elegans, and determining the lipofuscin level of the caenorhabditis elegans, the damage degree of dopaminergic neurons, the dopamine level and the expression and aggregation conditions of alpha-synuclein protein, so as to evaluate the risk of the Parkinson's disease induced by environmental pollutants; the environmental pollutant is 6: 2 chlorinated polyfluoroalkyl ether sulfonate. According to the method, the PD toxicity evaluation model is generated by constructing a behavior characteristic and molecular characteristic scheme and combining multi-strain nematode data, and the problem that in the prior art, the risk of inducing PD by environmental pollutants is difficult to comprehensively reveal due to the fact that a single dimension is concerned is solved.

The invention provides application of qi-blood foundation strengthening oral liquid in preparation of a medicine for building body and resisting aging, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by adopting the modes of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood not only has the effective component content, but also has the health-care effect. The oral liquid for consolidating qi and blood has the effects of improving the activity of superoxide dismutase of red blood cells and reducing the content of lipofuscin in tissues, can improve the exercise tolerance of rats, and has the effects of resisting aging and building the body.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a riptacaine cream as well as a preparation method and application thereof, and the preparation method of the riptacaine cream comprises the following steps: preparing carbomer gel, preparing an oil phase, preparing a water phase, primarily emulsifying, homogenizing and gelating, finely homogenizing and filling. According to the invention, polyoxyethylene (54) hydrogenated castor oil is innovatively used as an auxiliary material, triple functions of a co-melting solvent, an emulsifying agent and a stabilizing agent are realized at the same time, and any liquid grease, solvent or other surfactants do not need to be additionally added in the prescription. Through a unique'water-gel-oil 'composite structure design, oil drops are physically wrapped by a carbomer gel network and are positioned in network pores, so that the mechanical stability superior to that of a conventional emulsion is provided, and no layering is generated through high-speed centrifugal test verification. In conclusion, the invention develops the riptacaine preparation which has the advantages of few types of auxiliary materials, higher stability, quicker effect taking and capability of expanding a new dosage form and a new process.

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The invention discloses a diisoprene derivative as shown in a structural general formula (I) and a structural general formula (II), or pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, the diisoprene derivative has the activity of regulating the expression of a low-density lipoprotein receptor (LDLR), and can inhibit tumor cell proliferation, control inflammatory factor release, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation and inhibit tumor cell proliferation. The accumulation of retinal lipofuscin is reduced, macular degeneration is improved, and retinal injury is relieved. The diisoprene derivative can be used for treating diseases related to abnormal lipid metabolism, such as cardiovascular diseases, metabolic diseases, cancer, inflammation, retinal diseases and / or other diseases. # imgabs0 #

The invention belongs to the technical field of compound application, and particularly relates to coriaria lactone compounds, a preparation method thereof and application of the coriaria lactone compounds in oxidative stress resistance. The coriaria lactone compound can significantly inhibit oxidative stress damage of SH-SY5Y cells, and the cell survival rate of the coriaria lactone compound is increased to 79.6%. Meanwhile, the nematode anti-aging activity is achieved, generation of nematode lipofuscin is inhibited, and the highest inhibition rate is 45%. In an extreme oxidative stress experiment, the service life of the nematodes is prolonged, so that the coriaria lactone compound has an application prospect of treating and resisting aging diseases.

The invention discloses application of 3, 5, 6-trihydroxy-stilbene glucoside in preparation of an anti-aging product and an aging inhibitor. Researches find that the 3, 5, 6-trihydroxy-stilbene glucoside has the effects of delaying senescence of nematodes and prolonging the life of the nematodes, can reduce accumulation of lipofuscin of the nematodes, improve exercise ability and enhance stress resistance, so that senescence of the nematodes is delayed, the life of the nematodes is prolonged, and the 3, 5, 6-trihydroxy-stilbene glucoside can be used for preparing the medicine for resisting senescence and / or prolonging the life.

The invention discloses application of o-tolyl biguanide in preparation of a skin whitening product, the skin whitening product and a preparation method, and belongs to the technical field of skin care. It is found for the first time that o-tolyl biguanide can effectively inhibit generation of advanced glycosylation end products, namely carboxy methyl lysine (CML), lipofuscin and melanin when serving as a whitening active ingredient, and therefore the multi-channel whitening effect is achieved. The invention further provides a whitening product, the whitening product comprises the o-tolyl biguanide and the anionic surfactant which are similar in charge quantity, the o-tolyl biguanide is positively charged, the anionic surfactant is negatively charged, and the o-tolyl biguanide and the anionic surfactant can form a complex without net charge or with weak net charge. Furthermore, the stability of the o-tolyl biguanide in a whitening product system can be effectively improved, irreversible aggregation, flocculation or precipitation with common thickening agents such as carbomer is avoided, and the formula compatibility and stability of the o-tolyl biguanide are improved.

The invention discloses application of a composition containing lycium barbarum polysaccharide. The lycium barbarum polysaccharide is used for achieving the effects of resisting aging and removing lipofuscin, particularly, the specific lycium barbarum polysaccharide LBP1C can more remarkably reduce the level of transcription factors GATA4, activate key transcription regulatory factors of autophagy, reduce aging-related secretion phenotypes and inhibit accumulation of lipofuscin, and the lycium barbarum polysaccharide LBP1C has the effects of delaying aging, whitening skin and promoting healthy aging.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

The invention discloses a composition with a whitening effect. The composition is prepared from the following components in parts by mass: 47 to 51 parts of grape seed oil, 47 to 51 parts of pomegranate seed oil, 0.5 to 0.8 part of 4-butylresorcinol, 0.2 to 0.6 part of VC-IP (Vitamin C-IP) and 0.1 to 10 parts of isorhamnetin-3-O-neohesperidin. The invention also discloses a preparation method of the composition. The invention also discloses an essence oil containing the composition. The invention also discloses a face cream containing the composition. The invention also discloses application of the composition in preparation of cosmetics for skin whitening, spot fading and skin yellowing reduction. The composition provided by the invention establishes a multi-target synergistic pathway: 1, a blackness removal pathway for reducing the activation of oxidative stress such as ultraviolet rays on melanocytes; and 2, a jaundice removal pathway: inhibiting lipid peroxidation and promoting lipofuscin removal.

This invention discloses the application of cinnamyl flavanone alkaloids and phenylpropanol-substituted ester-type catechins in the preparation of drugs for treating or preventing aging and lowering lipids. In vivo experiments have confirmed that the cinnamyl flavanone alkaloids and phenylpropanol-substituted ester-type catechins of this invention, without reproductive toxicity to a *C. elegans* model, can prolong the average lifespan of nematodes, improve their motility, enhance their stress resistance, reduce endogenous ROS levels and lipofuscin content, and decrease the body fat content of nematodes. Therefore, the cinnamyl flavanone alkaloids and phenylpropanol-substituted ester-type catechins of this invention can be used in the preparation of drugs for treating or preventing aging and lowering lipids.

Cosmetic compositions comprise at least one decarboxylated oligopeptide and at least one pyracantha extract. The decarboxylated oligopeptide may be a decarboxylated dipeptide or decarboxylated tripeptide. The decarboxylated oligopeptide may be in free form or in salt form. The cosmetic composition may demonstrate capacity of preventing or slowing the lipofuscin generation and / or accumulation. A method for treating lipofuscin comprises the topical application of a cosmetic composition comprising at least one decarboxylated oligopeptide and at least one pyracantha extract.

The application belongs to the technical field of medicine, and discloses a method for screening antioxidant active ingredients of Fructus Schisandrae based on a Caenorhabditis elegans model. The method comprises the following operation steps: transferring wild-type N2 Caenorhabditis eleganss that are synchronously grown to the L4 stage to NGM culture plates to which active ingredient samples of Fructus Schisandrae are added and blank control NGM culture plates, as a sample group and a control group; observing and recording the survival rate, heat stress life span, antioxidant stress life span, swallowing frequency, head shaking frequency, movement ability, egg laying rate, lipofuscin and cellular reactive oxygen species level, antioxidant enzyme defense capacity of the nematodes, and completing antioxidant gene correlation analysis through transcriptome sequencing, and when the sample group treated by the active ingredients of Fructus Schisandrae has a significant difference compared with the control group, the active ingredients of Fructus Schisandrae have antioxidant activity.

The present invention relates to the fields of medicine and cosmetology, and discloses a multi-target freckle removal and whitening efficacy cell active peptide composition, its preparation method and cosmetic application. The composition includes raw materials such as hexapeptide-2, acetylcysteine, ergothioneine, alfalfa extract, resveratrol, vitamin E, asiaticoside, mandelic acid, ceramide, acetyl tetrapeptide-5, tranexamic acid, and carnosine. The composition can thicken the skin barrier; inhibit melanin synthesis and promote melanin metabolism; protect against ultraviolet rays and blue light, and repair sun damage; inhibit pigmentation caused by inflammation; improve vascular microcirculation; inhibit lipofuscin production; and promote carotene metabolism. The composition is applied to dermatology and cosmetology, effectively reducing skin darkening, dullness, yellowing, and red blood streaks, fading pigmentation and spots, reducing the a value of the red zone, improving skin gloss and whiteness, and having a multi-target freckle removal, whitening, brightening, and yellowing effect.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“Bispecific RBP4 / TTR ligand”) is a chemical entity that binds to both TTR and RBP4 in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

An anti-aging traditional Chinese medicine composition and its preparation method belong to the field of traditional Chinese medicine technology. The composition consists of the following components by weight: 3-60 parts of Polygonatum sibiricum, 1-70 parts of Astragalus membranaceus, 2-40 parts of Lycium barbarum, and 1-40 parts of Ganoderma lucidum spore powder. The method is as follows: soak the raw materials except for Ganoderma lucidum spore powder; decoct the raw materials 1-3 times; combine the decoctions obtained after several decoctions and concentrate them to obtain concentrated decoction; prepare the concentrated decoction into freeze-dried powder; add Ganoderma lucidum spore powder to the freeze-dried powder and stir evenly. The pharmacodynamic research results of the anti-aging of the present invention are as follows: (1) The test drug can significantly prolong the average lifespan of naturally aging nematodes by 30%, which is better than Erjingwan and the Western medicine NMN; (2) improve exercise, feeding ability and nervous system function; (3) improve antioxidant capacity: reduce the fluorescence intensity of ROS and lipofuscin, and improve the survival rate of nematodes after H2O2 stress stimulation; (4) improve telomerase activity; (5) improve cognitive dysfunction and learning and memory ability.

Disclosed in the present disclosure is a composition for skin aging resistance, skin whitening, or skin quality improvement containing, as an active ingredient, a metalloprotease derived from a strain of the genus Chryseobacterium, and / or a composition for inhibiting lipofuscin deposition or eliminating lipofuscin containing, as an active ingredient, the metalloprotease. The composition provides skin anti-aging, skin whitening or skin quality improving efficacy by inhibiting lipofuscin deposition or removing lipofuscin, and provides an effect of preventing, improving or treating diseases caused by lipofuscin deposition.

Autofluorescence is the inherent emission of light from cells or tissues that occurs when biological samples are exposed to different wavelengths of excitation light. Tissue autofluorescence is usually ascribed to biological components such as flavins, porphyrins, chlorophyll (in plants), collagen, elastin, red blood cells (RBCs), and lipofuscin. Tissue autofluorescence often presents a significant problem in microscopy, pathology, and surgical applications. Autofluorescence interferes and complicates signal detection in a variety of fluorescence microscopy methods. Tissue autofluorescence reduces the signal detection sensitivity, and in some cases may cause failure in the detection of fluorescent dye signals. Accordingly, there is a need for further improved methods to decrease the autofluorescence intensity from microscopy samples both in research and clinical venues. Described herein is a photobleaching device utilizing a light source tuned to the full spectrum of light to quench autofluorescence of a biological sample.

The present disclosure provides pharmaceutical compositions comprising i) a MsP1 enzyme and ii) one or more pharmaceutically acceptable carriers. The disclosure also provides methods comprising the pharmaceutical compositions for use in treating patients with various disease states, as well as related sequences and expression vectors.

The application discloses application of o-tolyl biguanide in preparation of skin whitening products, a whitening product and a preparation method, and belongs to the technical field of skin care. It is found for the first time that o-tolyl biguanide can effectively inhibit generation of late glycosylation end product carboxymethyl lysine (CML), lipofuscin and melanin when serving as a whitening active ingredient, thereby achieving a multi-pathway whitening effect. The application further provides a whitening product which comprises o-tolyl biguanide and an anionic surfactant with similar electric charge quantity; the o-tolyl biguanide is positively charged, and the anionic surfactant is negatively charged; the two can form a complex without net electric charge or with weak net electric charge, thereby effectively improving stability of the o-tolyl biguanide in the whitening product system, avoiding irreversible aggregation, flocculation or precipitation phenomenon with commonly used thickening agents such as carbomer, and improving formulation compatibility and stability of the o-tolyl biguanide.

The present application relates to a kind of composition with anti-glycation inhibiting RAGE and lightening effect, its preparation method, preparation product and application, belong to medical instrument field, medical or dressing preparation field, biological medicine manufacturing technology field and preparation manufacturing technology field.The composition includes sapota bark extract, tetrahydrocurcumin, mirabilis jalapa extract, surfactant, polyol, phospholipid and solvent.The preparation method provided in the present application includes using 1,3-butanediol with 25%~35% 1,3-butanediol formula amount of 1,3-butanediol and surfactant, sapota bark extract, tetrahydrocurcumin are mixed and dissolved;And the remaining polyol and phospholipid are mixed and the like steps, improve the light stability and high temperature stability of the obtained composition, have unexpected technical effects, and simple operation, without high pressure mean equipment, equipment cost is low.In addition, the composition provided in the present application has high bioavailability, has good antioxidant lightening effect and inhibiting lipofuscin and RAGE level effect.

The invention provides radix ophiopogonis oligosaccharide with an anti-aging effect as well as a preparation method and application of the radix ophiopogonis oligosaccharide. The radix ophiopogonis oligosaccharide is prepared by adopting a water extraction and alcohol precipitation method, and the preparation process has the characteristics of being green and safe. According to analysis of HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) and the like, the polymerization degree of the prepared dwarf lilyturf tuber oligosaccharide is mainly distributed between 2 and 25, and the dwarf lilyturf tuber oligosaccharide belongs to the field of natural oligosaccharide. Animal experiment results show that the oligosaccharide can significantly reduce accumulation of lipofuscin and lipid in an aging model, prolong life, improve exercise, swallowing and reproductive capacity, and up-regulate antioxidant enzyme level, and shows excellent anti-aging activity.

A system and method are provided for bimodal detection and / or imaging of macular pigments. Fundus autofluorescence spectroscopy is applied in a first and a second region of an eye to measure fluorescence values from the fluorescing pigment (e.g., lipofuscin). The first region can be a macula, which has a higher density of macular pigments, and the second region can be in the peripheral retina, which has a lower density of macular pigments. Fundus reflection spectroscopy is applied in the first and a second region of an eye, as a baseline image, to determine absorptions due to other pigments (e.g., melanin) than the macular pigments and the fluorescing pigment. The density of macular pigments is determined using the measures fluorescence values and the absorptions due to other pigments.

The application belongs to the technical field of disease diagnosis, and particularly relates to a method for label-free fluorescent early detection of tumors in children. In order to construct a non-invasive early diagnosis method for neuroblastoma, the application finds through research that the fluorescence intensity of plasma of tumor patients is significantly reduced under 280 nm excitation, and tryptophan (TRP) is the main source of the difference fluorescence through metabolomics verification. It is also found that the fluorescence lifetime of flavin / lipofuscin of patients in the late stage is significantly prolonged. The TRP fluorescence intensity and the flavin / lipofuscin fluorescence lifetime parameters are combined to build a model, and the ROC analysis result shows that the AUC of the combination for distinguishing normal people from patients in early and late stages and early and late stages is 0.77, 0.92 and 0.99 respectively. The detection method does not need fluorescent labeling, is simple and convenient to operate, low in cost, excellent in diagnosis performance, suitable for screening of children patients, and can provide core optical parameters for research and development of portable diagnostic equipment, and has good clinical popularization value.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.